The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations
- 256 Downloads
The vitamin K epoxide reductase (VKORC1) is a key enzyme in the vitamin K cycle impacting various biological processes. VKORC1 genetic variability has been extensively studied in the context of warfarin pharmacogenetics revealing different distributions of VKORC1 haplotypes in various populations. We previously identified the VKORC1 Asp36Tyr mutation that was associated with warfarin resistance and with distinctive ethnic distribution. In this study, we performed haplotype analysis using Asp36Tyr and seven other VKORC1 markers in Ashkenazi and Ethiopian-Jewish and non-Jewish individuals. The VKORC1 variability was represented by nine haplotypes (V1-V9) that could be grouped into two distinct clusters (V1-V3 and V4-V9) with intra-cluster difference limited to two nucleotide changes. Phylogeny analysis suggested that these haplotypes could have developed from an ancestral variant, the common V8 haplotype (40 % in all population samples), after ten single mutation events. Asp36Tyr was exclusive to the V5 haplotype of the second cluster. Two haplotypes V5 and V4, distinguished only by Asp36Tyr, were prevalent in both Ethiopian population samples. The V2 haplotype, belonging to the first cluster, was the second most prevalent haplotype in the Ashkenazi population sample (15.8 %) but relatively uncommon in the Ethiopian origin (4.5-4.7 %). We discuss the genetic diversity among studied populations and its potential impact on warfarin-dose management in certain populations of African and European origin.
KeywordsAllele frequencies Gene flow Haplotype analysis Population genetics Warfarin (Coumarin) resistance
We thank Dr. Collen Masimirembwa and his group for providing DNA samples from the African Biobank.
This study was supported by the Israeli Ministry of Industry Nofar program #39410. This study was performed in partial fulfilment of the requirements for Ms Sominsky’s M.Sc. thesis, submitted to the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel.
Conflict of interest
Dr. Gak holds a 40 % stake in patent PCT application no. WO2007IL00405, filed in March 2007, entitled “Methods and kits for determining predisposition to warfarin resistance”, which includes the VKORC1 D36Y variant. None of the other authors have any conflicts of interest to report.
- Atzmon G, Hao L, Pe’er I, Velez C, Pearlman A, Palamara PF, Morrow B, Friedman E, Oddoux C, Burns E, Ostrer H (2010) Abraham’s children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet 86(6):850–859PubMedCentralPubMedCrossRefGoogle Scholar
- Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G, Khusnutdinova EK, Balanovsky O, Semino O, Pereira L, Comas D, Gurwitz D, Bonne-Tamir B, Parfitt T, Hammer MF, Skorecki K, Villems R (2010) The genome-wide structure of the Jewish people. Nature 466(7303):238–242PubMedCrossRefGoogle Scholar
- Harrington DJ, Siddiq S, Allford SL, Shearer MJ, Mumford AD (2011) More on: endoplasmic reticulum loop VKORC1 substitutions cause warfarin resistance but do not diminish gamma-carboxylation of the vitamin K-dependent coagulation factors. J Thromb Haemost 9(5):1093–1095. doi: 10.1111/j.1538-7836.2011.04249.x PubMedCrossRefGoogle Scholar
- Korostishevsky M, Kremer I, Kaganovich M, Cholostoy A, Murad I, Muhaheed M, Bannoura I, Rietschel M, Dobrusin M, Bening-Abu-Shach U, Belmaker RH, Maier W, Ebstein RP, Navon R (2006) Transmission disequilibrium and haplotype analyses of the G72/G30 locus: suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel. Am J Med Genet B Neuropsychiatr Genet 141B(1):91–95. doi: 10.1002/ajmg.b.30212 PubMedCrossRefGoogle Scholar
- Kurnik D, Qasim H, Sominsky S, Lubetsky A, Markovits N, Li C, Stein CM, Halkin H, Gak E, Loebstein R (2012) Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Haemost 108(4):781–788. doi: 10.1160/TH12-03-0151 PubMedCentralPubMedCrossRefGoogle Scholar
- Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT (2008a) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5):511–526. doi: 10.2217/146224184.108.40.2061 PubMedCentralPubMedCrossRefGoogle Scholar
- Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N (2008b) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10):1445–1458. doi: 10.2217/146224220.127.116.115 PubMedCentralPubMedCrossRefGoogle Scholar
- Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827–3834. doi: 10.1182/blood-2009-12-255992 PubMedCentralPubMedCrossRefGoogle Scholar
- Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974):537–541. doi: 10.1038/nature02214 PubMedCrossRefGoogle Scholar
- Rost S, Fregin A, Hunerberg M, Bevans CG, Muller CR, Oldenburg J (2005) Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thromb Haemost 94(4):780–786PubMedGoogle Scholar
- Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE (2007) Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin Pharmacol Ther 81(5):742–747. doi: 10.1038/sj.clpt.6100144 PubMedCrossRefGoogle Scholar
- Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329–2333PubMedCrossRefGoogle Scholar
- Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel S, Perry K, Meltzer DO, McLeod HL, Johnson JA (2013) VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians. Thromb Haemost 109(6):1045–1050. doi: 10.1160/TH12-10-0789 PubMedCrossRefGoogle Scholar
- Shiloh Y (2008) The land of Cush and Ethiopian Jewry. Available: http://www.biu.ac.il/JH/Parasha/eng/noah/shil.html. Accessed 2011 Jan 6
- Shuen AY, Wong BY, Fu L, Selby R, Cole DE (2012) Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem 45(6):397–401. doi: 10.1016/j.clinbiochem.2012.01.002 PubMedCrossRefGoogle Scholar
- Tabachnikov S, Aklillu E, Masimirembwa C, Maimbo M, Ken-Dror G, Dvoskin I, Cohen Y, Rechavi G, Amariglio N, Loebstein R, Kurnik D, Halkin H, Gak E (2010) Tracing of the Jewish-Ashkenazi mutation to ancient African populations. Abstract of Frontiers in Genetics VI The Genetic Society of Israel Annual Meeting 2010 Weizmann Institute of Science, Israel, p 112Google Scholar
- Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101–110PubMedCrossRefGoogle Scholar
- Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, Rost S, Seifried E, Muller CR, Oldenburg J (2011) Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 9(1):109–118. doi: 10.1111/j.1538-7836.2010.04095.x PubMedCrossRefGoogle Scholar